Floatz logo

MIDAZOLAM

Bipolar Disorder I

King's College LondonSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

33 Active assets in the Bipolar Disorder I cohort.

Asset / SponsorPhaseRating
Lurasidone
Massachusetts General Hospital
Phase 4BBB
LITHIUM, ELEMENTAL
Alzamend Neuro, Inc.
Phase 4BBB
Cipralex
Massachusetts General Hospital
Phase 4BBB
Olanzapine
Alkermes, Inc.
Phase 4BBB
Asenapine
Organon and Co
Phase 3BBB

View all 50 →

Same molecule, other indications

MIDAZOLAM is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
75 / 100
View asset →
neuralgiaDormant
BBB
Indicative ·
75 / 100
View asset →
epilepsyDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →